Spots Global Cancer Trial Database for Identification of Novel High Quality Methylated DNA Markers in Renal Tumors: Whole Methylome Discovery, Tissue Validation, and Feasibility Testing In Blood and Urine, The INQUIRE Study

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Trial Identification

Brief Title: Identification of Novel High Quality Methylated DNA Markers in Renal Tumors: Whole Methylome Discovery, Tissue Validation, and Feasibility Testing In Blood and Urine, The INQUIRE Study

Official Title: Identification of Novel High Quality Methylated DNA Markers in Renal Tumors: Whole Methylome Discovery, Tissue Validation, and Feasibility Testing in Blood and Urine

Study ID: NCT06339138

Conditions

Chromophobe Renal Cell Carcinoma

Clear Cell Papillary Renal Tumor

Clear Cell Renal Cell Carcinoma

Kidney Oncocytoma

Papillary Renal Cell Carcinoma

Urothelial Carcinoma

Interventions

Non-Interventional Study

Study Description

Brief Summary: This study is being done to collect blood, tissue and urine samples to identify a novel high quality methylated DNA marker in patients with renal tumors.

Detailed Description: PRIMARY OBJECTIVES: I. In tissue, to discover and validate DNA methylation markers (MDMs) for detection of malignant renal and urothelial tumors. II. In blood, to assess the accuracy of candidate MDMs from above for detection of malignant renal and urothelial tumors. OUTLINE: This is an observational study. Participants may undergo blood, urine, and tissue sample collection on study. Participants' medical records are also reviewed.